EP2243496A3 - Contrast agents to target extracellular matrix - Google Patents

Contrast agents to target extracellular matrix Download PDF

Info

Publication number
EP2243496A3
EP2243496A3 EP10169506A EP10169506A EP2243496A3 EP 2243496 A3 EP2243496 A3 EP 2243496A3 EP 10169506 A EP10169506 A EP 10169506A EP 10169506 A EP10169506 A EP 10169506A EP 2243496 A3 EP2243496 A3 EP 2243496A3
Authority
EP
European Patent Office
Prior art keywords
extracellular matrix
contrast agents
target extracellular
target
biomodifier
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP10169506A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP2243496A2 (en
Inventor
Dagfinn Lovhaug
Morten Eriksen
Herge Brincker Fjerdinstad
Andrew Healey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare AS
Original Assignee
GE Healthcare AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare AS filed Critical GE Healthcare AS
Publication of EP2243496A2 publication Critical patent/EP2243496A2/en
Publication of EP2243496A3 publication Critical patent/EP2243496A3/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0056—Peptides, proteins, polyamino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
    • A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
    • A61K49/0032—Methine dyes, e.g. cyanine dyes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/085—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier conjugated systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Magnetic Resonance Imaging Apparatus (AREA)
  • Steroid Compounds (AREA)
EP10169506A 2004-11-22 2005-11-21 Contrast agents to target extracellular matrix Withdrawn EP2243496A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NO20045081 2004-11-22
EP05817391A EP1814598B1 (en) 2004-11-22 2005-11-21 Contrast agents to target extracellular matrix

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP05817391.5 Division 2005-11-21

Publications (2)

Publication Number Publication Date
EP2243496A2 EP2243496A2 (en) 2010-10-27
EP2243496A3 true EP2243496A3 (en) 2012-12-26

Family

ID=36182407

Family Applications (2)

Application Number Title Priority Date Filing Date
EP10169506A Withdrawn EP2243496A3 (en) 2004-11-22 2005-11-21 Contrast agents to target extracellular matrix
EP05817391A Expired - Lifetime EP1814598B1 (en) 2004-11-22 2005-11-21 Contrast agents to target extracellular matrix

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP05817391A Expired - Lifetime EP1814598B1 (en) 2004-11-22 2005-11-21 Contrast agents to target extracellular matrix

Country Status (17)

Country Link
US (1) US8182790B2 (enExample)
EP (2) EP2243496A3 (enExample)
JP (2) JP5116480B2 (enExample)
KR (1) KR20070091609A (enExample)
CN (1) CN101107016B (enExample)
AT (1) ATE494913T1 (enExample)
AU (1) AU2005307195A1 (enExample)
BR (1) BRPI0518328A2 (enExample)
CA (1) CA2586621A1 (enExample)
DE (1) DE602005025911D1 (enExample)
ES (1) ES2358745T3 (enExample)
IL (1) IL182898A0 (enExample)
MX (1) MX2007006050A (enExample)
NO (1) NO20073039L (enExample)
RU (1) RU2007118385A (enExample)
WO (1) WO2006054904A2 (enExample)
ZA (1) ZA200705043B (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0610395D0 (en) * 2006-05-25 2006-07-05 Ge Healthcare Ltd Novel imaging agents
CN101528270A (zh) * 2006-08-28 2009-09-09 通用电气健康护理有限公司 基于68Ga标记的肽的放射性药物
JP2008266194A (ja) * 2007-04-19 2008-11-06 Hiroshi Tanaka 分子プローブの原料として有用な新規有機化合物
GB0722650D0 (en) * 2007-11-19 2007-12-27 Ge Healthcare Ltd Novel imaging method
JP5604305B2 (ja) * 2007-12-13 2014-10-08 アンセルム（アンスチチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル） 線維症の非侵襲性の特異的イメージングのための、ポリペプチド、環状ポリペプチドおよびそれを含む医薬
EP2244741B1 (en) 2008-01-18 2015-03-25 VisEn Medical, Inc. Fluorescent imaging agents
AU2009246397B2 (en) 2008-05-13 2013-01-17 University Of Kansas Metal abstraction peptide (MAP) tag and associated methods
GB0814722D0 (en) * 2008-08-12 2008-09-17 Ge Healthcare Ltd Treatment monitoring
GB0910013D0 (en) * 2009-06-10 2009-07-22 Ge Healthcare Ltd PET imaging of fibogenesis
KR100991716B1 (ko) * 2009-10-22 2010-11-04 경북대학교 산학협력단 광학영상 조영제, 그 용도 및 장치
CN102504603B (zh) * 2011-10-20 2014-01-29 中国海洋大学 一种多聚物与生物染色剂的偶合物及其制备方法和用途
WO2013181461A2 (en) 2012-06-01 2013-12-05 University Of Kansas Metal abstraction peptide with superoxide dismutase activity
US20170050989A1 (en) * 2013-12-03 2017-02-23 The General Hospital Corporation Molecular Imaging Probes
CN117623996B (zh) * 2022-08-10 2025-07-22 中国药科大学 一种二价keap1-nrf2抑制剂、制备方法及其医药用途

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077145A2 (en) * 2000-04-12 2001-10-18 Amersham Health As Integrin binding peptide derivatives
WO2002055111A2 (en) * 2000-11-27 2002-07-18 Bristol Myers Squibb Medical I Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
WO2003006491A2 (en) * 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4647447A (en) 1981-07-24 1987-03-03 Schering Aktiengesellschaft Diagnostic media
US4615876A (en) * 1983-04-25 1986-10-07 Curators Of The University Of Missouri Macrocyclic complexes of technetium-99m for use as diagnostic radionuclides
US4687659A (en) 1984-11-13 1987-08-18 Salutar, Inc. Diamide-DTPA-paramagnetic contrast agents for MR imaging
US5268486A (en) 1986-04-18 1993-12-07 Carnegie-Mellon Unversity Method for labeling and detecting materials employing arylsulfonate cyanine dyes
US6048982A (en) 1986-04-18 2000-04-11 Carnegie Mellon University Cyanine dyes as labeling reagents for detection of biological and other materials by luminescence methods
DE68927479T2 (de) 1988-05-02 1997-04-03 Phanos Tech Inc Verbindungen, zusammensetzungen und verfahren zum binden von bio-affektions-substanzen an oberflächenmembranen von bioteilchen
GB8903022D0 (en) * 1989-02-10 1989-03-30 Celltech Ltd Chemical compounds
CA2124329C (en) 1991-11-27 2008-11-18 Gregory A. Kopia Compounds, compositions and methods for binding bio-affecting substances to surface membranes of bio-particles
ATE314097T1 (de) * 1996-10-28 2006-01-15 Amersham Health As Kontrastmittel
CA2269985A1 (en) 1996-10-28 1998-05-07 Aslak Godal Improvements in or relating to diagnostic/therapeutic agents
AU5871798A (en) * 1997-01-29 1998-08-18 Nycomed Imaging As Polymers
US6348599B1 (en) 1997-07-28 2002-02-19 Nycomed Amersham Plc Cyanine dyes
US5942637A (en) * 1998-03-30 1999-08-24 North Dakota State University Research Foundation Compounds containing tetradecachlorocyclohexasilane dianion
US6852318B1 (en) * 1998-05-08 2005-02-08 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
WO1999058139A2 (en) * 1998-05-08 1999-11-18 The Regents Of The University Of California Methods for detecting and inhibiting angiogenesis
JP2000095758A (ja) * 1998-09-18 2000-04-04 Schering Ag 近赤外蛍光造影剤および蛍光造影方法
US6230777B1 (en) 1999-02-04 2001-05-15 Midmac Systems, Inc. Filter forming and joining apparatus
NO20004795D0 (no) * 2000-09-26 2000-09-26 Nycomed Imaging As Peptidbaserte forbindelser
GB0116815D0 (en) 2001-07-10 2001-08-29 Nycomed Amersham Plc Improved chelator conjugates
GB0206750D0 (en) 2002-03-22 2002-05-01 Amersham Plc Radiofluorination methods
JP2006510576A (ja) 2002-06-17 2006-03-30 カルテラ、アクチボラグ アテローム性動脈硬化症のプラーク形成の進行を防止するためのインテグリンα１０鎖の方法および使用
US7063158B2 (en) 2003-06-16 2006-06-20 Deepwater Technologies, Inc. Bottom tensioned offshore oil well production riser
NO20033115D0 (no) 2003-07-08 2003-07-08 Amersham Health As Peptid-baserte forbindelser
GB0317815D0 (en) * 2003-07-30 2003-09-03 Amersham Health As Imaging agents
WO2005019247A2 (en) * 2003-08-15 2005-03-03 Board Of Regents, The University Of Texas System Cyclic peptide and imaging compound compositions and uses for targeted imaging and therapy
US7431914B2 (en) * 2003-11-24 2008-10-07 Ge Healthcare As Contrast agent
CN1925876A (zh) * 2004-03-04 2007-03-07 通用电气医疗集团股份有限公司 用于诊断和治疗的血管紧张素肽类似物和螯合剂的缀合物
RU2393167C2 (ru) * 2004-06-16 2010-06-27 Джи-И Хелткер АС Пептидные соединения
AU2005254915B2 (en) 2004-06-16 2011-10-13 Ge Healthcare As Peptide-based compounds

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001077145A2 (en) * 2000-04-12 2001-10-18 Amersham Health As Integrin binding peptide derivatives
WO2002055111A2 (en) * 2000-11-27 2002-07-18 Bristol Myers Squibb Medical I Simultaneous imaging of cardiac perfusion and a vitronectin receptor targeted imaging agent
WO2003006491A2 (en) * 2001-07-10 2003-01-23 Amersham Health As Peptide-based compounds for targeting intergin receptors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
HAGEN VAN P M ET AL: "EVALUATION OF A RADIOLABELLED CYCLIC DTPA-RGD ANALOGUE FOR TUMOUR IMAGING AND RADIONUCLIDE THERAPY", INTERNATIONAL JOURNAL OF CANCER, NEW YORK, NY, US, vol. 90, no. 4, 20 August 2000 (2000-08-20), pages 186 - 198, XP001002235, ISSN: 0020-7136 *
HAUBNER R ET AL: "RADIOLABELED TRACERS FOR IMAGING OF TUMOR ANGIOGENESIS AND EVALUATION OF ANTI-ANGIOGENIC THERAPIES", CURRENT PHARMACEUTICAL DESIGN, BENTHAM SCIENCE PUBLISHERS, SCHIPHOL, NL, vol. 10, no. 13, 1 May 2004 (2004-05-01), pages 1439 - 1455, XP008042350, ISSN: 1381-6128 *
J SCHNEE: "Angiotensin II, adhesion, and cardiac fibrosis", CARDIOVASCULAR RESEARCH, vol. 46, no. 2, 1 May 2000 (2000-05-01), pages 264 - 268, XP055044428, ISSN: 0008-6363, DOI: 10.1016/S0008-6363(00)00044-4 *
LUDBROOK SB ET AL: "The integrin alphavbeta3 is a receptor for the latency-associated peptides of transforming growth factors beta1 and beta3", BIOCHEMICAL JOURNAL, THE BIOCHEMICAL SOCIETY, LONDON, GB, vol. 369, 15 January 2003 (2003-01-15), pages 311 - 318, XP007913102, ISSN: 0264-6021 *

Also Published As

Publication number Publication date
JP5116480B2 (ja) 2013-01-09
AU2005307195A1 (en) 2006-05-26
CA2586621A1 (en) 2006-05-26
DE602005025911D1 (de) 2011-02-24
NO20073039L (no) 2007-08-16
JP2012207027A (ja) 2012-10-25
IL182898A0 (en) 2007-08-19
ATE494913T1 (de) 2011-01-15
EP1814598B1 (en) 2011-01-12
EP1814598A2 (en) 2007-08-08
JP2008520658A (ja) 2008-06-19
KR20070091609A (ko) 2007-09-11
ZA200705043B (en) 2008-09-25
US8182790B2 (en) 2012-05-22
ES2358745T3 (es) 2011-05-13
CN101107016A (zh) 2008-01-16
MX2007006050A (es) 2007-11-14
WO2006054904A2 (en) 2006-05-26
WO2006054904A3 (en) 2007-04-05
EP2243496A2 (en) 2010-10-27
CN101107016B (zh) 2011-11-16
US20090208412A1 (en) 2009-08-20
RU2007118385A (ru) 2008-12-27
BRPI0518328A2 (pt) 2008-11-11

Similar Documents

Publication Publication Date Title
ZA200705043B (en) Contrast agents to target extracellular matrix
WO1998018497A3 (en) Contrast agents
EP2060272A3 (en) Vitamin-mitomycin conjugates
WO2006079120A3 (en) Fc-fusion constructs binding to phosphatidylserine and their therapeutic use
CA2406650A1 (en) Cationic diagnostic, imaging and therapeutic agents associated with activated vascular sites
WO2002036161A3 (en) Novel targeted compositions for diagnostic and therapeutic use
WO2001082975A3 (en) Membrane-permeant peptide complexes for medical imaging
WO1998018496A3 (en) Contrast agents
WO2005089813A3 (en) Receptor-avid exogenous optical contrast and therapeutic agents
BRPI0418552A (pt) compostos de alvejamento de piperidinila que seletivamente ligam-se à integrinas
WO2005034909A3 (en) Hyperbranched polymer conjugates via non-enzymatic cleavable linker
EP2147679A3 (en) Compositions and methods for modulating blood-brain barrier transport
EP2260858A3 (en) Monomethylvaline compounds capable of conjugation to ligands
AU4488800A (en) Novel cyanine and indocyanine dye bioconjugates for biomedical applications
WO1999048536A3 (en) Delivery of long lasting therapeutic agents by forming covalent attachments in vivo
EP2253333A3 (en) Contrast Agents for Myocardial Perfusion Imaging
WO2008136869A3 (en) Methods and compositions related to targeting wounds, regenerating tissue, and tumors
AU5076799A (en) Trifunctional reagent for conjugation to a biomolecule
WO2002087497A3 (en) Therapeutic agent/ligand conjugate compositions, their methods of synthesis and use
AU2003256446A1 (en) Targeting and tracking of cells to specific organs and tissues in vivo
WO1996008274A3 (en) Conjugates of heparin-binding epidermal growth factor-like growth factor with targeted agents
WO2005029066A3 (en) Diagnostic markers and pharmacological targets in heart failure and related reagents and methods of use thereof
WO2007008080A3 (en) Optical imaging contrast agents
BRPI0414864A (pt) composição farmacêutica multiparticulada compreendendo ácido micofenólico ou micofenolato de sódio e combinação com rapamicida
WO2004110255A3 (en) Antineoplastic agents targeted via glut transporters

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 1814598

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

PUAL Search report despatched

Free format text: ORIGINAL CODE: 0009013

AK Designated contracting states

Kind code of ref document: A3

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 49/00 20060101AFI20121121BHEP

17P Request for examination filed

Effective date: 20130624

RBV Designated contracting states (corrected)

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20140115

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

INTG Intention to grant announced

Effective date: 20170515

RIN1 Information on inventor provided before grant (corrected)

Inventor name: FJERDINGSTAD, HERGE, BRINCKER

Inventor name: LOVHAUG, DAGFINN

Inventor name: ERIKSEN, MORTEN

Inventor name: HEALEY, ANDREW

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170926